Secondary non Hodgkin's lymphomas;Les lymphomes non hodgkiniens secondaires

Bulletin du Cancer

Volumn 85, Issue 3, 1998, Pages 217-231

  Cappelaere, Paul ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Chronic lymphocytic leukemia; Hodgkin's disease; Immunodeficiency; Secondary non Hodgkin's lymphoma

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; CANCER RISK; CHILD; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PROBABILITY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; SPLENOMEGALY;

HODGKIN DISEASE; HUMANS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RISK FACTORS; SYNDROME;

EID: 0031960926     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol 1928; 4: 285-92.
2. Warthin AS. The genetic neoplastic relationship of Hodgkin's disease aleukaemic and leukaemic lymphoblastoma and mycosis fungoides. Ann Surg 1931; 93: 153-61.
3. Herbut PA, Miller FR, Erf IA. The relation of Hodgkin's disease, lymphosarcoma and reticulum cell sarcoma. Am J Pathol 1945; 21: 233-45.
4. Razis DV, Diamond HD, Craver LF. Hodgkin's disease associated with other malignant tumors and certain non-neoplastic diseases. Am J Med Sci 1959; 238: 327-35.
5. Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 1979; 300: 452-8.
6. Kim H, Bedetti C, Nboggs D. The development of non-Hodgkin's lymphoma following therapy for Hodgkin's disease. Cancer 1980; 46: 2596-602.
7. Armitage JO, Dick FR, Goeken JA, Foucar K, Gingrich RD. Second lymphoid malignant neoplasms occurring in patients treated for Hodgkin's disease. Arch Intern Med 1983; 143: 445-50.
8. Jacquillat C, Khayat D, Desprez-Curely JP, Weil M, Brocheriou C, Auclerc G, et al. Non-Hodgkin's lymphoma occurring after Hodgkin's disease: four new cases and a review of the literature. Cancer 1984; 53: 459-62.
9. Zarate-Osorno A, Medeiros LJ, Longo DL, Jaffe ES. Non-Hodgkin's lymphomas arising in patients successfully treated for Hodgkin's disease: a clinical, histologie and immunophenotypic study of 14 cases. Am J Surg Pathol 1992; 16: 885-95.
10. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830-7.
11. Kobayashi Y, Arimoto H, Watanabe S. Second malignant lymphomas and leukemias m the National Cancer Center from 1962 to 1987. Jpn J Cancer Res 1990; 81: 570-7.
12. Bennett MH, Mac Lennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. Ann Oncol 1991; 2 (suppl. 2): 83-92.
13. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's disease. Ann Oncol 1992; 3 (suppl. 4): S117-S128.
14. Sont JK, Van Stiphout WAHJ, Noordijk EM, Molenaar J, Zwetsloot-Schonk JHM, Willemze R, et al. Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Hematol 1992; 65: 213-8.
15. Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol 1993; 4: 125-31.
16. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, Van den Belt-Dusebout AW, Van Kerkhoff EHM. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312-25.
17. Sankila R, Pukkala F, Teppo L. Risk of subsequent malignant neoplasms among 470 000 cancer patients in Finland, 1953-1991. Int J Cancer 1995; 60: 461-70.
18. Sankila R, Garwicz S, Olsen JH, Dollner H, Hertz H, Kreuger A, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five nordic countries. J Clin Oncol 1996; 14: 1442-6.
19. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996; 87: 3625-32.
20. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality alter Hodgkin's disease. Semin Radiation Oncol 1996; 6: 225-42.
21. Swerdlow AJ, Barber JA, Horwich A, Cunningham D, Milan S, Omar RZ. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden hospital. Br J Cancer 1997; 75: 116-23.
22. Robinson E, Bar-Deroma R, Epelbaum R, Rennert G, Neugut AI. Clinical characteristics of non-Hodgkin's lymphoma as a second primary tumor: a population-based survey. Leukemia and Lymphoma 1996; 20: 297-301.
23. De Angelis LM. Primary central nervous system lymphoma as a secondary malignancy. Cancer 1991; 67: 1431-5.
24. Reni M, Ferreri AJM, Zoldan MC, Villa E. Primary brain lymphomas in patients with a prior concomitant malignancy. J Neuro Oncol 1997; 32: 135-42.
25. Robertson LK, Pugh W, O'Brien S, Kantarjian H, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985-9.
26. Jacobs RH, Vokes EE, Golomb HM. Second malignancies in hairy cell leukemia. Cancer 1985; 56: 1462-7.
27. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 1990; 50: 3605-9.
28. Frassoldati A, Lamparelli R, Federico M, Annino L, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Leuk Lymphoma 1994; 13: 307-16.
29. Arnalich F, Camacho J, Jimenez C, Lahoz C, Patron M. Occurrence of immunoblastic B-cell lymphoma in hairy cell leukemia. Cancer 1987; 59: 1161-4.
30. Vardiman JW, Colomb HM. Autopsy findings in hairy cell leukemia. Sem Oncol 1984; 11: 370-80.
31. Kampmeier P, Spielberger R, Dickstein J, Mick R, Colomb H, Vardiman JW. Increased incidence of second neoplasms in patients treated with interferon α 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994; 83: 2931-8.
32. Troussard X, Henry-Amar M, Flandrin G. Second cancer risk after interferon therapy? Blood 1994; 84: 3242-4.
33. Federico M, Frassoldati A, Lamparelli T, Foa R, Brugiatelli M, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 1994; 5: 725-31.
34. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity and long-term follow-up. J Clin Oncol 1997; 15: 1138-42.
35. Kurzrock R, Strom SS, Este E, O'Brien S, et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 1997; 15: 1803-10.
36. Cimino G, Papa G, Tura S, Mazza P, Rossi Ferrini PL, Bosi A, et al. Second primary cancer following Hodgkin's disease: updated results of an italian multicentric study. Clin Oncol 1991; 9: 432-7.
37. Koletsky AJ, Bertino R, Farber LR, Prosnitz LR, Kapp DS, Fischer D, et al. Second neoplasms in patients with Hodgkin's disease following combined modality therapy - The Yale experience. J Clin Oncol 1986; 4: 311-7.
38. Kaldor JM, Day NE, Band P, Choi NW, Clarke EA, Coleman MP, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987; 39: 571-85.
39. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745-51.
40. Olsen JH, Garwicz S, Hertz H, Jonmundsson G, Langmark F, Lanning M, et al. Second malignant neoplasms after cancer in childhood or adolescence. Br Med J 1993; 307: 1030-6.
41. Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Blood 1994; 84: 1209-15.
42. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Mac Lennan KA. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer 1993; 68: 1006-11.
43. Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1997; 15: 3060-6.
44. Coleman MP, Bell CMJ, Fraser P. Second primary malignancy after Hodgkin s disease, ovarian cancer and cancer of the testis: a population-based cohort study. Br J Cancer 1987; 56: 349-55.
45. Eguiguren JM, Ribeiro RC, Pui CH, Hancock ML, Pratt CB, Head DR, et al. Secondary non-Hodgkin's lymphoma after treatment for childhood cancer. Leukemia 1991; 5: 908-11.
46. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaloy S, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993; 11: 255-61.
47. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76-81.
48. Faguet GB. Chronic lymphocytic leukemia: an updated review. J Clin Oncol 1994; 12: 1974-90.
49. Salloum E, Tallini G, Levy A, Cooper DL. Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. Cancer Invest 1996; 14: 527-33.
50. Dray M, Ferme C, Rain JD, Gisselbrecht C, Flandrin G. Rémission complète d'un lymphome Localisé de type Burkitt survenant après maladie de Hodgkin. Presse Méd 1985; 14: 2062-3.
51. Henry-Amar M, Joly F. Late complications after Hodgkin's disease. Ann Oncol 1996; 7 (suppl. 4): S115-26.
52. Variakojis D, Anastasi J. Unresolved issues concerning Hodgkin's disease and its relationship to non-Hodgkin's lymphoma. Am J Clin Pathol 1993; 99: 436-44.
53. Jaffe ES, Zarate-Osorno A, Kingma DW, Raffeld M, Medeiros J. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphoma. Ann Oncol 1994; 5 (suppl. 1): S7-11.
54. Hell K, Hansmann ML, Pringle JH, Lauder I, Fischer R. Combination of Hodgkin's disease and diffuse large cell lymphoma: an in situ hybridization study for immunoglobulin light chain messenger RNA. Histopathology 1995; 27: 491-9.
55. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983; 51: 2293-300.
56. Hansmann ML, Zwingers T, Boske A, Loffler H, Lennert K. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 1984; 108: 321-30.
57. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997; 337: 453-8.
58. Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997; 337: 459-65.
59. Wickert RS, Weisenburger DD, Tierens A, Greiner TC, Chan WC. Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent of subsequent large-cell lymphoma of B lineage. Blood 1995; 86: 2312-20.
60. Greiner TC, Gascoyne RD, Anderson ME, Kingmad DW, Adomat SA, Said J, Jaffe ES. Nodular lymphocyte-predominant Hodgkin's disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 1996; 88: 657-66.
61. Casey TT, Cousar JB, Mangum M, Williams ME, Lee JT, et al. Monomorphic lymphomas arising in patients with Hodgkin's disease. Correlation of morphologic, immunophenotypic, and molecular genetic findings in 12 cases. Am J Pathol 1990; 136: 81-94.
62. Matolcsy A, Inghirami G, Knowles DM. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). Blood 1994; 83: 1363-72.
63. Cuneo A, De Angeli C, Grazia M, Piva N, Bigoni R, et al. Richter's syndrome in a cas of atypical chronic lymphocytic leukaemia with the t(11:14)(q13;q32): role for a p53 exon 7 gene mutation. Br J Haematol 1996; 92: 375-81.
64. Travis LB, Curtis RE, Hankey BF, Fraumeni JF. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 1422-7.
65. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 1997; 15: 458-65.
66. Juliusson G, Christiansen I, Hansen MM, Johnson S, Kimby E, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160-6.
67. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570-4.
68. Boivin JF, Hutchinson GB, Zauber AG, Berstein L, Davis FG, Michel RP, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995; 87: 732-41.
69. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, Mac Lennan KA. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2,846 patients in the British National Lymphoma Investigation. Br Med J 1992; 304: 1137-43.
70. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol 1995; 146: 1113-20.
71. Socie G, Kolb B. Malignant diseases after bone marrow transplantation: the case for tumor banking and continued reporting to registries. Bone Marrow Transplantation 1995; 16: 493-5.
72. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with a malignancy in Epstein-Batr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996; 88: 242-51.